Bavarian Nordic
BAVA.COBAVA.CO · Stock Price
Historical price data
Overview
Bavarian Nordic's mission is to protect public health through innovative immunization strategies, establishing itself as a critical player with a dual-revenue model. The company has achieved significant commercial success with its travel health portfolio and solidified its public health role through long-standing government contracts for its non-replicating smallpox/mpox vaccine. Its strategy centers on leveraging its integrated capabilities and MVA platform to expand its commercial portfolio and respond to emerging infectious disease threats, driving sustainable growth.
Technology Platform
Proprietary Modified Vaccinia Ankara (MVA) platform, a non-replicating viral vector system enabling safe and rapid development of vaccines against diverse infectious diseases.
Pipeline
66| Drug | Indication | Stage | Watch |
|---|---|---|---|
| IMVAMUNE® | Vaccination | Approved | |
| VAXCHORA (Cholera Vaccine, Live, Oral) | Cholera (Disorder) | Approved | |
| PROSTVAC-V + PROSTVAC-F + GM-CSF + Placebo | Prostate Cancer Metastatic | Phase 3 | |
| PXVX0200 + placebo | Cholera | Phase 3 | |
| MVA-BN standard regimen + MVA-BN standard regimen (Administe... | Neonate | Phase 3 |
Funding History
4Opportunities
Risk Factors
Competitive Landscape
Competes with large vaccine multinationals (GSK, Sanofi) in travel health and with government contractors (Emergent BioSolutions) in biodefense. Its key competitive moat is the superior safety profile of its non-replicating MVA platform, making it the preferred choice for stockpiles and vulnerable populations.
Company Timeline
Founded in Hørsholm, Denmark
Grant: $100.0M
IPO — $40.0M
PIPE: $200.0M